We are live on ! Find out more
IMNM icon

Immunome

29 hedge funds and large institutions have $15.4M invested in Immunome in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more call options, than puts

Call options by funds: $240K | Put options by funds: $163K

0.8% less ownership

Funds ownership: 23.07% → 22.27% (-0.8%)

3% less funds holding

Funds holding: 30 → 29 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

59% less capital inflows, than outflows

Capital inflows: $567K | Capital outflows: $1.38M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
29
Holders Change
-1
Holders Change %
-3.33%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
6
Reduced
9
Closed
4
Calls
$240​K
Puts
$163​K
Net Calls
+$77​K
Net Calls Change
-⁠$818​K

IMNM Hedge Fund Activity: Q1 2022 in Review

29 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2022, worth a combined $15.4M — down 58% from $36.4M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of IMNM and 3 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 6 added.

The largest buyer was Baldwin Investment Management, opening a new position worth an estimated $190K. The largest seller was Morgan Stanley, cutting an estimated $486K.

  • 29 institutional investors held Immunome (IMNM) as of Q1 2022, down from 30 in Q4 2021.
  • Funds reported $15.4M of Immunome stock for Q1 2022, down 58% quarter-over-quarter.
  • 3 funds opened new Immunome positions in Q1 2022 and 4 closed out, a net change of -1 holder.
  • The largest Immunome buyer in Q1 2022 was Baldwin Investment Management, an estimated $190K added.
  • The largest Immunome seller in Q1 2022 was Morgan Stanley, an estimated $486K sold.

Based on aggregated 13F filings for Q1 2022.